Detalles de la búsqueda
1.
ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach.
Cancer Treat Res Commun
; 39: 100802, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38428066
2.
Blood tumor mutational burden and dynamic changes in circulating tumor DNA predict response to pembrolizumab treatment in advanced non-small cell lung cancer.
Transl Lung Cancer Res
; 12(5): 971-984, 2023 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37323168
3.
Plasma Immune Proteins and Circulating Tumor DNA Predict the Clinical Outcome for Non-Small-Cell Lung Cancer Treated with an Immune Checkpoint Inhibitor.
Cancers (Basel)
; 15(23)2023 Nov 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38067332
4.
Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials.
Transl Lung Cancer Res
; 11(6): 953-963, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35832438
Resultados
1 -
4
de 4
1
Próxima >
>>